ABSI vs ZBIO Stock Comparison

ABSI currently leads ZBIO in this stock comparison, with AIQ scores of 53 vs 47. The clearest difference is momentum, while ZBIO has the stronger risk resilience profile.

Market data as of Nov 15, 2026 market close· AIQ score gap 6 points
ABSI
Healthcare
vs
ZBIO
Healthcare
ABSI
Absci Corporation
Leads
Price
$8.45
Day move
-7.5%
AIQ Score
53/100
Best edge
Momentum
Sector
Healthcare
ZBIO
Zenas BioPharma, Inc.
Price
$28.01
Day move
+1.34%
AIQ Score
47/100
Best edge
Risk Resilience
Sector
Healthcare

What is the main difference between ABSI and ZBIO?

ABSI leads the current stock comparison as Absci Corporation, with the clearest separation coming from momentum and the broader AIQ evidence mix.

AlgovestIQ AIQ Comparison

Absci Corporation vs Zenas BioPharma, Inc.

Data as of Nov 15, 2026· market close· Healthcare· Coverage 63/66 fields· High confidence
AIQ VerdictFragileAIQ Comparison Conviction 3/10

ABSI leads

ABSI leads by 6 AIQ points, primarily on Momentum, but the lead has narrowed from 10 points over 30 sessions. Wall Street currently favors ZBIO on target upside.

Fragile: 2 of 5 evidence groups support ABSI, its lead is narrowing, and its current signal state is conflicted.

Evidence agreement: 2 of 5Comparison trend: Weakening
ABSI

Absci Corporation

Leads
AIQ Score
53/100
AIQ Edge Score
9/10
ZBIO

Zenas BioPharma, Inc.

AIQ Score
47/100
AIQ Edge Score
4/10

The Algovestiq AIQ Score currently favors ABSI over ZBIO, 53 versus 47 as of Nov 15, 2026. ABSI's advantage is driven primarily by stronger momentum, while ZBIO holds the stronger risk resilience profile. ABSI also shows the weaker technical structure relative to its 50-day moving average, though analyst target upside currently favors ZBIO. 2 of 5 covered evidence groups favor ABSI today, and the comparison is rated Fragile on stability: only 2 of 5 covered evidence groups agree. ABSI lead: Weakening — the AIQ differential moved from 10 to 6 points over 30 sessions.

Compare Absci Corporation and Zenas BioPharma, Inc. across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.

Currently unavailable

Performance over time

Price return from daily closes; distributions are not included.

ABSI
+116.7%
ZBIO
+54.3%

Price return comparison

Growth of $10,000, price only

ABSI $21,667 · ZBIO $15,433

Split-adjusted closes only. Distributions are excluded, which understates the return of any fund or stock that pays them.

Compare ABSI and ZBIO against another ticker

Open a multi-ticker workspace without changing this focused pair page.

Basic: 2 symbols·Explorer: 3 symbols·Pro and Premium: 5 symbols·Your limit: 2

AIQ Factor Divergence

Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.

ABSI advantage
0
ZBIO advantage
  • Risk Resilience30 vs 39
    ZBIO +9
  • Momentum85 vs 78
    ABSI +7
  • Quality26 vs 25
    Even

2 of 5 evidence groups favor ABSI. ABSI’s edge is concentrated in momentum; ZBIO keeps a meaningful risk resilience edge.

What changed since the last close

Latest scored session 2026-11-13, compared against the prior scored session 2026-11-12.

ABSI0 AIQ

Largest factor move: Quality -2, not enough on its own to move the overall score.

New signals

  • TSI Bearish Crossover — bearish, momentum, short horizon
ZBIO+1 AIQ

Largest factor move: Momentum +2

New signals

  • Beta Spike Warning — bearish, risk_regime, long horizon
  • Low Volume Rally Warning — bearish, volume, short horizon (0.61x)
  • RSI Midline Reclaim — bullish, momentum, short horizon

ABSI's lead narrowed by 1 AIQ point in the latest session.

Deeper signal detail for each name lives on its own signals page — ABSI and ZBIO both carry a full feed there.

The central trade-off

ABSI (Absci Corporation): the stronger current systematic profile, led by momentum.

ZBIO (Zenas BioPharma, Inc.): the counter-case, on risk resilience, fundamentals, analyst expectations.

The AIQ Score and Wall Street therefore point in different directions on this pair.

Which one fits your objective

The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.

Balanced

ABSI

ABSI on the overall AIQ Score, which weights Quality and Value most heavily.

Growth

ZBIO

ZBIO on combined revenue and EPS growth.

Value

Even

The two are level on Value.

Momentum

ABSI

ABSI on the Momentum factor, by 7 points.

Lower downside

ZBIO

ZBIO on Risk Resilience, by 9 points.

Analyst upside

ZBIO

ZBIO on implied upside to the consensus price target.

AIQ vs Wall Street

The model and the Street disagree here: AIQ favors ABSI, analyst targets favor ZBIO. That disagreement is the most useful thing on this page.

MeasureABSIZBIONote
Implied upside to target+71.6%+96.4%ZBIO has more room
Target dispersion+6.9%0%Lower is tighter analyst agreement
ConsensusBuyBuyContext, not a primary driver
Analysts covering128Higher coverage generally improves confidence

The two are measuring different things. The AIQ Score reads current fundamentals, valuation, trend and risk; analyst targets price forward expectations. A divergence of this kind is either a contrarian opportunity or a sign the model is missing something already priced in — it is worth resolving before acting on either.

Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.

AIQ Agreement Matrix

2 of 5 covered evidence groups favor ABSI. A wide gap backed by one group is a weaker case than a narrow gap backed by five.

Evidence groupFavorsReading
AIQ ScoreABSI53 vs 47
FundamentalsZBIOon balancerevenue growth -4.4% vs 9%; EPS growth 9.5% vs 6.8%; TTM ROE -15.2% vs -51.3%; gross margin -26.5% vs -6.6%; operating margin -91.6% vs -47.9% — ZBIO takes 3 of 5 decided legs, not all of them
ValuationNot coveredNot covered
TechnicalsABSIPrice vs 50-day -12.5% vs -2%; vs 200-day 23.7% vs 10.5%
Risk ResilienceZBIORisk Resilience 30 vs 39
Analyst expectationsZBIOTarget upside 71.6% vs 96.4%

✓ agrees with the overall verdict · ✕ points the other way. Groups marked “not covered” lack data on one or both of ABSI and ZBIO and are excluded from the count.

AIQ Decision Stability

Fragile

The conclusion is sensitive to small changes. Treat the lead as provisional and watch the flip conditions below.

  • The AIQ gap is moderate at 6 points.
  • Only 2 of 5 covered evidence groups agree. (argues the conclusion is provisional)
  • The leader's advantage has been narrowing. (argues the conclusion is provisional)
  • The lead has been steady session to session. (supports the conclusion holding)
  • The leader is throwing conflicting signals. (argues the conclusion is provisional)
  • Signal direction runs against the verdict: the leader is net-bearish while the laggard is net-bullish. (argues the conclusion is provisional)

Stability combines the score gap, how broadly the evidence agrees, how steady the lead has been across daily snapshots, the current signal state on both names, and analyst dispersion on ABSI.

How the comparison changed

120 daily snapshots · May 27 – Nov 13

ABSI lead: Weakening — the AIQ differential moved from 10 to 6 points over 30 sessions.

May 27ABSI leads above the line · ZBIO leads belowNov 13
Today
ABSI +6
53 vs 47
7 sessions ago
ABSI +9
55 vs 46
30 sessions ago
ABSI +10
53 vs 43
90 sessions ago
ABSI +12
57 vs 45

The lead changed hands 3 times in this window, most recently on Sep 24 when ABSI moved ahead of ZBIO.

AIQ Signal Divergence

Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.

ABSIConflicted

2 bullish / 3 bearish / 1 neutral, conflicted

Only ABSI

  • Accumulation Pattern — bullish, volume, medium horizon (1.30x)
  • MACD Histogram Expanding Bearish — bearish, momentum, short horizon
  • TSI Bearish Crossover — bearish, momentum, short horizon
ZBIOConflicted

3 bullish / 2 bearish / 1 neutral, conflicted

Only ZBIO

  • EMA Ribbon Expansion Bullish — bullish, trend, medium horizon
  • Low Volume Rally Warning — bearish, volume, short horizon (0.61x)
  • RSI Midline Reclaim — bullish, momentum, short horizon

Both carry 3 more signals that do not separate them: Golden Cross Active, ATR Expansion - Breakout Mode, Beta Spike Warning.

ABSI leads the comparison while carrying a conflicted signal state, which is one reason the stability rating is not higher.

Price vs model alignment

Whether the latest session's price move confirms what the model did over the same session, or contradicts it.

ABSINo material change

Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price -7.5%, AIQ 0 points).

ZBIOConfirmed strength

Price and the AIQ Score both moved up over the latest session (price +1.34%, AIQ +1 points).

What would flip this result

A state, not a forecast. These are the specific, observable changes that would reverse the verdict — not a price prediction.

  1. 1ZBIO closes the Momentum gap — currently 7 points behind, the largest single contributor to ABSI's edge.
  2. 2ZBIO's Beta Spike Warning resolves — a bearish risk_regime rule currently active against it.
  3. 3ABSI's conflicting signal state resolves bearish — it currently carries 2 bullish and 3 bearish rules at once.
  4. 4The narrowing continues — the lead has already given back 4 points over 30 sessions, and a further 6-point move would eliminate ABSI's advantage entirely.

The full evidence

Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.

Fundamentals

ZBIO leads on balance
MetricABSIZBIO
Revenue growth (YoY)-4.4%9%
EPS growth (YoY)9.5%6.8%
Gross margin-26.5%-6.6%
Operating margin-91.6%-47.9%
Return on equity (TTM)-15.2%-51.3%
Debt to equity0.021.42

Performance

Split across windows
MetricABSIZBIO
1 week (5 sessions)-16.9%-0.9%
1 month (20 sessions)2.4%12.8%
3 months (63 sessions)-8.5%-8.2%
6 months (126 sessions)64.7%52.7%
Year to date142.1%-22.9%
1 year (252 sessions)148.5%-21.8%

Technicals

ABSI has the stronger structure
MetricABSIZBIO
RSI (14)4250.1
ADX (14)13.812.2
Price vs 50-day-12.5%-2%
Price vs 200-day23.7%10.5%
Volatility (1M, annualized)126.6%65.7%

Risk

ZBIO is the more resilient
MetricABSIZBIO
Beta3.280.75
Sharpe ratio1.580.26
Sortino ratio2.740.34
Max drawdown-42.8%-64.8%
Current drawdown-30.2%-35.1%
Annualized volatility104.2%95.3%
Value at risk (95%)-8.2%-7.3%

Straight answers

Each answer is regenerated from the current snapshot, not written once and left to age.

Which is better, ABSI or ZBIO?

On the Algovestiq AIQ Score, ABSI is the stronger of the two as of Nov 15, 2026, scoring 53 against ZBIO's 47. The edge comes from momentum. ZBIO is not without a case — it holds the better risk resilience profile, which matters more if that is the objective you are optimizing for. This is a systematic score, not a recommendation: it ranks the two on the same evidence, it does not know your holding period or tax position.

Is ABSI or ZBIO the better buy right now?

ABSI carries the stronger systematic profile as of Nov 15, 2026, and the comparison is rated Fragile — 2 of 5 covered evidence groups agree. A Fragile rating means the conclusion is sensitive: only 2 of 5 covered evidence groups agree. Treat the lead as provisional.

Why does the AIQ Score favor ABSI over ZBIO?

The composite weights Quality, Value, Momentum and Risk Resilience. ZBIO leads Risk Resilience by 9 points; ABSI leads Momentum by 7 points. Where the two split, the factor with the larger weight carries the result.

Which has more analyst upside, ABSI or ZBIO?

Analyst price targets imply +71.6% upside for ABSI and +96.4% for ZBIO, so the Street currently favors ZBIO. That points the opposite way to the AIQ Score, which favors ABSI. The two are measuring different things: the model reads current fundamentals, valuation, trend and risk; the Street is pricing forward expectations. A divergence of this kind is either a contrarian opportunity or a sign the model is missing something the analysts have already priced — it is the single most useful row on this page to investigate. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.

Which is better value, ABSI or ZBIO?

Neither name separates on the peer-relative Value factor. The two are level on Value. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.

Which has stronger growth, ABSI or ZBIO?

ZBIO on combined revenue and EPS growth. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.

Which has stronger momentum, ABSI or ZBIO?

ABSI on the Momentum factor, by 7 points. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.

Which is riskier, ABSI or ZBIO?

ZBIO is the more resilient of the two, so the other name carries the higher downside risk. ZBIO on Risk Resilience, by 9 points. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.

Is ABSI more profitable than ZBIO?

The profitability evidence is mixed: gross margin -26.5% vs -6.6%; operating margin -91.6% vs -47.9%; ttm roe -15.2% vs -51.3%. ABSI leads on one measure and ZBIO on two measures, and there is no single profitability composite that resolves the split — which of the two reads as "more profitable" depends on whether you weight pricing power or operating leverage.

Is ABSI's lead over ZBIO getting stronger or weaker?

ABSI lead: Weakening — the AIQ differential moved from 10 to 6 points over 30 sessions. This is measured from 120 daily comparison snapshots between 2026-05-27 and 2026-11-13. The lead has changed hands 3 times in that window, most recently on 2026-09-24, when ABSI moved ahead of ZBIO.

What would change the ABSI vs ZBIO verdict?

The result is a state, not a forecast, so it changes when the underlying evidence changes. Concretely: ZBIO closes the Momentum gap — currently 7 points behind, the largest single contributor to ABSI's edge; ZBIO's Beta Spike Warning resolves — a bearish risk_regime rule currently active against it; ABSI's conflicting signal state resolves bearish — it currently carries 2 bullish and 3 bearish rules at once; the narrowing continues — the lead has already given back 4 points over 30 sessions, and a further 6-point move would eliminate ABSI's advantage entirely.

What do the current signals say about ABSI and ZBIO?

ABSI: 2 bullish / 3 bearish / 1 neutral, conflicted. ZBIO: 3 bullish / 2 bearish / 1 neutral, conflicted. A conflicted state means bullish and bearish rules are active on the same name at once — the technical evidence is not pointing one way, and a decision taken on it carries more timing risk. The most decision-relevant rule on ABSI is Golden Cross Active (bullish, long horizon). On ZBIO it is Golden Cross Active (bullish, long horizon).

Compare ABSI and ZBIO with others

Continue your research

This page answers which of the two. These answer the questions on either side of it.

How this comparison is scored

The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.

The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.

How to use side-by-side comparison →

This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.